Tilray, Inc. Reports Third Quarter 2019 Financial Results


Ryan Allway

November 17th, 2019

News


Revenue Increased 409% to $51.1 (C$67.8) Million in the Third Quarter of 2019 Compared to the Prior Year Period

International Medical Revenue Grew More Than Five-Fold Compared to the Prior Year Period

NANAIMO, British Columbia–(BUSINESS WIRE)–Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, reports financial results for the third quarter ended September 30, 2019. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“We are in the early days of seeing our strategic initiatives bear fruit – including our European expansion, brand portfolio evolution and strategic partnership product launches. We continue to expect significant growth in the fourth quarter and into 2020.”

Tweet this

“Our performance in the third quarter, including solid revenue growth and sequential gross margin expansion, reflects the positive business trends we have underway,” said Brendan Kennedy, Tilray’s President and Chief Executive Officer. “We are in the early days of seeing our strategic initiatives bear fruit – including our European expansion, brand portfolio evolution and strategic partnership product launches. We continue to expect significant growth in the fourth quarter and into 2020.”

He continued, “Beyond that, our strong global infrastructure and supply chain are a critical competitive advantage and our team is focused on maximizing the substantial opportunity we have to deliver long-term, sustainable value to our shareholders.”

Third Quarter 2019 Financial Highlights

  • Revenue increased 408.6% to $51.1 million (C$67.8 million), compared to the third quarter of last year, driven by the Canadian adult-use market, the Manitoba Harvest acquisition, and growth in international medical markets as a result of the first GMP certification of the Portugal facility. Excluding excise tax, revenue was $48.2 (C$64.1) million.

Three months ended September 30,

Nine months ended September 30,

2019

2018

$ Change

% Change

2019

2018

$ Change

% Change

Adult-use

$

15,834

$

$

15,834

N/A

$

38,756

$

$

38,756

N/A

ACMPR (direct to patient & bulk)

13,909

9,098

4,811

53

%

30,750

25,743

5,007

19

%

Hemp products

15,650

15,650

N/A

41,167

41,167

N/A

International – medical

5,708

949

4,759

501

%

9,370

1,856

7,514

405

%

Total revenue

$

51,101

$

10,047

$

41,054

409

%

$

120,043

$

27,599

$

92,444

335

%

Excise tax included in revenue

$

2,931

$

$

2,931

N/A

$

8,707

$

$

8,707

N/A

  • Total kilogram equivalents sold increased over six-fold to 10,848 kilograms from 1,613 kilograms in the prior year period.
  • Average net selling price per gram decreased to $3.25 (C$4.32) compared to $6.21 (C$8.26) in the prior year period. The average net selling price excluding excise taxes for adult-use was $2.98 (C$3.96) per gram for the third quarter of 2019. The decrease was due to a shift in product and channel mix.
  • Gross margin increased sequentially to 31% from 27% in the prior quarter and was flat compared to the third quarter of 2018.
  • Net loss for the quarter was $35.7 million or $0.36 per share compared to a loss of $18.7 million or $0.20 per share for the prior year period. Adjusted EBITDA was a loss of $23.5 million compared to a loss of $7.4 million in the prior year period. The increased net loss and Adjusted EBITDA declines were primarily due to the increase in operating expenses related to growth initiatives, expansion of international teams, and the addition of Manitoba Harvest and Natura businesses.

Business Highlights

  • Signed definitive agreement with Privateer Holdings, Inc. to extend lock-up for up to two years and provide for orderly release of the 75 million Tilray common shares held by Privateer Holdings, Inc.
  • Announced definitive agreement to acquire 420 Investments Ltd. (“FOUR20”), an adult-use cannabis retail operator headquartered in Calgary, Alberta. The transaction is expected to close by the end of the first quarter of 2020.
  • Significant capacity expansion:
    • Increased international export capacity with an additional 20 hectares (50 acres) of outdoor cultivation space in Portugal through a Definitive Agreement with Esporão, one of the largest and most sophisticated agricultural businesses in Portugal. This agreement expands Tilray’s total production and manufacturing footprint to 3.4 million square feet worldwide.
  • Key international market developments:
    • Exported first shipment of medical cannabis from EU Campus in Portugal to Germany to supply patients in need.
    • Imported GMP-certified finished medical cannabis oil solutions into Ireland for nationwide distribution under the Medical Cannabis Access Programme.
  • Expanding our brand portfolio:
    • Fluent Beverage Company, a joint venture between Anheuser‐Busch InBev and Tilray through subsidiaries Labatt Breweries of Canada and High Park, announced plans to distribute CBD Beverages in Canada in December 2019 once regulations allow.1
    • High Park™, a subsidiary of Tilray, Inc., unveiled the second phase of its adult-use product portfolio set to launch throughout Canada over the course of the next year as permitted by regulations. The expanded broad-based portfolio includes innovative cannabis products and formats, including CBD beverages, edibles, and vape products.2
    • Acquired Smith & Sinclair, an innovative U.K.-based confectionary company that will introduce CBD-infused consumer products under the brand, Pollen, in the U.S. and U.K. within applicable regulations.
  • Clinical research developments:
    • Imported medical cannabinoids into the United States to support two clinical trials led by NYU School of Medicine for patients with Alcohol Use Disorder and Post-Traumatic Stress Disorder.
    • Imported medical cannabis into the United States from Canada for a new clinical trial evaluating the efficacy of medical cannabis as a treatment for taxane-induced peripheral neuropathy (TIPN) secondary to treatment with paclitaxel or docetaxel.3 TIPN affects more than 67 percent of women undergoing breast cancer treatment.

Conference Call

The Company will host a conference call to discuss these results today at 5:00 p.m. ET. Investors interested in participating in the live call can dial 877-489-6528 from the U.S. and 629-228-0736 internationally. A telephone replay will be available approximately two hours after the call concludes through Tuesday, November 26, 2019, by dialing 855-859-2056 from the U.S., or 404-537-3406 from international locations, and entering confirmation code 7038019.

There will also be a simultaneous, live webcast available on the Investors section of the Company’s website at www.tilray.com. The webcast will be archived for 30 days.

About Tilray®

Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in 13 countries spanning five continents.

1 Announced October 10, 2019
2 Announced October 16, 2019
3 Announced October 24, 2019

Forward Looking Statements

This press release contains “forward-looking statements”, which may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, including statements regarding our growth potential, the sustainability of growth, demand for our products and the medical and adult-use cannabis markets, anticipated plans for strategic partnerships and acquisitions, and the closing of the downstream merger with Privateer Holdings, Inc. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Please see the heading “Risk Factors” in Tilray’s Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on August 13, 2019, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.

Use of Non-U.S. GAAP Financial Measures

To supplement its financial statements, the Company provides investors with information related to Adjusted EBITDA, which is not a financial measure calculated in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). Adjusted EBITDA is calculated as net income (loss) before interest expense, net; other income, net; deferred income tax expense (recovery), current income tax expense; foreign exchange loss (gain), net; depreciation and amortization expense; stock-based compensation expense; acquisition-related (income) expense; and amortization of inventory step-up. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. The Company believes Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. Management uses Adjusted EBITDA to compare the Company’s performance to that of prior periods for trend analyses and planning purposes. Adjusted EBITDA is also presented to the Company’s Board of Directors.

Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. Non-U.S. GAAP measures exclude significant expenses that are required by U.S. GAAP to be recorded in the Company’s financial statements and are subject to inherent limitations.

TILRAY, INC.

Condensed Consolidated Statements of Net Loss and Comprehensive Loss

(in thousands of U.S. dollars, except for share and per share data, unaudited)

Three months ended September 30,

Nine months ended September 30,

2019

2018

2019

2018

Revenue

$

51,101

$

10,047

$

120,043

$

27,599

Cost of sales

35,248

6,979

86,532

16,458

Gross profit

15,853

3,068

33,511

11,141

General and administrative expense

19,978

7,001

49,240

16,488

Sales and marketing expense

16,974

3,493

39,161

9,061

Depreciation and amortization expense

3,190

529

7,438

1,032

Stock-based compensation expense

8,315

11,245

21,206

16,877

Research and development expense

2,315

802

4,891

2,416

Loss from equity method investments

1,837

1,837

Acquisition-related (income) expense, net

(13,454

)

10

(6,598

)

10

Operating loss

(23,302

)

(20,012

)

(83,664

)

(34,743

)

Foreign exchange loss (gain), net

2,585

(1,591

)

1,153

913

Interest expense, net

8,687

480

26,018

1,393

Finance income from ABG Profit Participation Arrangement

(210

)

(557

)

Other income, net

(1,313

)

(225

)

(5,661

)

(422

)

Loss before income taxes

(33,051

)

(18,676

)

(104,617

)

(36,627

)

Deferred income tax expense (recovery)

2,432

(3,987

)

Current income tax expense

195

24

402

87

Net loss

$

(35,678

)

$

(18,700

)

$

(101,032

)

$

(36,714

)

Net loss per share – basic and diluted

(0.36

)

(0.20

)

(1.04

)

(0.39

)

Weighted average shares used in computation of net loss per

share – basic and diluted

98,130,507

93,144,042

96,742,626

93,144,042

Net loss

$

(35,678

)

$

(18,700

)

$

(101,032

)

$

(36,714

)

Foreign currency translation loss

(4,863

)

(451

)

(2,414

)

(538

)

Unrealized (loss) gain on cash equivalents and investments

(301

)

345

Other comprehensive loss

(5,164

)

(451

)

(2,069

)

(538

)

Comprehensive loss

$

(40,842

)

$

(19,151

)

$

(103,101

)

$

(37,252

)

TILRAY, INC.

Condensed Consolidated Balance Sheets

(in thousands of U.S. dollars, except for share and par value data, unaudited)

September 30, 2019

December 31, 2018

Assets

Current assets

Cash and cash equivalents

$

100,159

$

487,255

Short-term investments

22,213

30,335

Accounts receivable, net of allowance for doubtful accounts of $612 and $292, respectively

36,040

16,525

Other receivables

2,886

969

Inventory

110,487

16,211

Prepaid expenses and other current assets

58,895

3,007

Total current assets

330,680

554,302

Property and equipment, net

166,489

80,214

Intangible assets, net

329,928

4,486

Goodwill

163,041

Investments

42,318

16,911

Deposits and other assets

7,744

754

Total assets

$

1,040,200

$

656,667

Liabilities

Current liabilities

Accounts payable

58,688

10,649

Accrued expenses and other current liabilities

71,387

14,818

Accrued obligations under capital lease

127

470

Total current liabilities

130,202

25,937

Accrued obligations under capital lease

9,166

8,286

Deferred tax liability

57,100

4,424

Convertible Notes, net of issuance cost

427,983

420,367

Total liabilities

$

624,451

$

459,014

Stockholders’ equity

Class 1 common stock ($0.0001 par value, 250,000,000 shares authorized;

16,666,667 shares issued and outstanding)

2

2

Class 2 common stock ($0.0001 par value; 500,000,000 shares authorized;

83,605,076 and 76,504,200 shares issued and outstanding, respectively

8

8

Additional paid-in capital

623,254

302,057

Accumulated other comprehensive income

1,694

3,763

Accumulated deficit

(209,209

)

(108,177

)

Total stockholders’ equity

415,749

197,653

Total liabilities and stockholders’ equity

$

1,040,200

$

656,667

Three months ended September 30,

Nine months ended September 30,

2019

2018

2019

2018

Adjusted EBITDA reconciliation:

Net loss

$

(35,678

)

$

(18,700

)

$

(101,032

)

$

(36,714

)

Depreciation and amortization expense

4,686

1,404

10,441

2,552

Stock-based compensation expense

8,315

11,245

21,206

16,877

Acquisition-related (income) expense, net

(13,454

)

10

(6,598

)

10

Foreign exchange loss (gain), net

2,585

(1,591

)

1,153

913

Interest expense, net

8,687

480

26,018

1,393

Other income, net

(1,313

)

(225

)

(5,661

)

(422

)

Amortization of inventory step-up

2,041

Deferred income tax expense (recovery)

2,432

(3,987

)

Current income tax expense

195

24

402

87

Adjusted EBITDA

$

(23,545

)

$

(7,353

)

$

(56,017

)

$

(15,304

)

Three months ended September 30,

Nine Months Ended September 30,

2019

2018

2019

2018

Adjusted net loss reconciliation:

Net loss

$

(35,678

)

$

(18,700

)

$

(101,032

)

$

(36,714

)

Acquisition-related (income) expense, net

(13,454

)

10

(6,598

)

10

Amortization of inventory step-up

2,041

Adjusted net loss

$

(49,132

)

$

(18,690

)

$

(105,589

)

$

(36,704

)

Adjusted net loss per share – basic and diluted

(0.50

)

(0.20

)

(1.09

)

(0.39

)

Weighted average shares used in computation of adjusted net loss per share – basic and diluted

98,130,507

93,144,042

96,742,626

93,144,042

 

Contacts

Media, Global: Chrissy Roebuck, +1-833-206-8161, news@tilray.com
Investors: Rachel Perkins, +1-646-277-1221, rachel.perkins@icrinc.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading